Cover [Abstract]
Entity Registrant Name
Entity Central Index Key
Document Type
Amendment Flag
Entity Voluntary Filers
Current Fiscal Year End Date
Entity Well Known Seasoned Issuer
Entity Small Business
Entity Shell Company
Entity Emerging Growth Company
Entity Current Reporting Status
Document Period End Date
Entity Filer Category
Document Fiscal Period Focus
Document Fiscal Year Focus
Entity Common Stock Shares Outstanding
Entity Public Float
Document Annual Report
Document Transition Report
Entity Interactive Data Current
Entity File Number
Entity Incorporation State Country Code
Entity Tax Identification Number
Entity Address Address Line 1
Entity Address City Or Town
Entity Address State Or Province
Entity Address Postal Zip Code
City Area Code
Local Phone Number
Security 12b Title
Security Exchange Name
Trading Symbol
Equity Components [Axis]
Preferred Stock [Member]
CONSOLIDATED BALANCE SHEETS
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
[Assets, Current]
Property and equipment, net
Intangible assets, net
Goodwill
Right to use assets
Deposits and other assets
TOTAL ASSETS
[Assets]
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities
Current portion of deferred revenue
Current portion of lease obligations
Total current liabilities
[Liabilities, Current]
Senior notes payable, net of discount
Deferred revenue, net of current portion
Subordinated note payable, net of discount
Lease obligations, net of current portion
Other non-current liabilities
TOTAL LIABILITIES
[Liabilities]
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding
Common Stock - voting, $0.0001 par value, 150,000,000 shares authorized, 104,902,888 and 59,318,355 shares issued and outstanding
Additional paid-in capital
Accumulated deficit
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
[Liabilities and Equity]
STOCKHOLDERS' EQUITY
Preferred stock, shares par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
CONSOLIDATED STATEMENTS OF OPERATIONS
REVENUES:
Product revenue
License revenue
Total revenues
[Revenues]
OPERATING EXPENSES:
Cost of product revenue (exclusive of amortization expense shown below)
Research and development
Plasma center operating expenses
Amortization of intangible assets
Selling, general and administrative
Total operating expenses
[Operating Expenses]
LOSS FROM OPERATIONS
[Operating Income (Loss)]
OTHER INCOME (EXPENSE):
Interest income
Interest expense
[Interest Expense]
Gain (loss) on extinguishment of debt
Gain on transfer of plasma center assets
Other expense
Other expense, net
[Nonoperating Income (Expense)]
NET LOSS
[Net Income (Loss) Attributable to Parent]
BASIC AND DILUTED LOSS PER COMMON SHARE
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and Diluted
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY
Statement [Table]
Statement [Line Items]
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Balance, shares
[Shares, Issued]
Balance, amount
Stock-based compensation
Warrants issued in connection with note payable
Issuance of common stock, net of offering expenses, shares
Issuance of common stock, net of offering expenses, amount
Stock options exercised, shares
Stock options exercised, amount
Net loss
Vesting of Restricted Stock Units, shares
Vesting of Restricted Stock Units, amount
Balance, shares
Balance, amount
CONSOLIDATED STATEMENTS OF CASH FLOWS
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss on disposal of fixed assets
Stock-based compensation
Amortization of debt discount
(Gain) loss on extinguishment of debt
Gain on transfer of plasma center assets
Amortization of license revenue
Changes in operating assets and liabilities:
Accounts receivable
Inventories
[Increase (Decrease) in Inventories]
Prepaid expenses and other current assets
[Increase (Decrease) in Prepaid Expense]
Deposits and other assets
[Increase (Decrease) in Other Operating Assets]
Accounts payable
[Increase (Decrease) in Accounts Payable]
Accrued expenses
Other current and non-current liabilities
Net cash used in operating activities
[Net Cash Provided by (Used in) Operating Activities]
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment
[Payments to Acquire Property, Plant, and Equipment]
Proceeds from the sale of property and equipment
Net cash used in investing activities
[Net Cash Provided by (Used in) Investing Activities]
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on notes payable
[Repayments of Long-term Debt]
Payment of end of end of term fee
[Payments for Other Fees]
Proceeds from issuance of common stock, net of offering expenses
Proceeds from the exercise of stock options
Payment of debt refinancing fees
Proceeds from issuance of note payable
Payment of debt issuance costs
[Payments of Debt Issuance Costs]
Payments on finance lease obligations
[Payments for Leasing Costs]
Net cash provided by financing activities
[Net Cash Provided by (Used in) Financing Activities]
Net increase (decrease) in cash and cash equivalents
[Cash and Cash Equivalents, Period Increase (Decrease)]
Cash and cash equivalents, including restricted cash - beginning of year
Cash and cash equivalents - end of year
ORGANIZATION AND BUSINESS
1. ORGANIZATION AND BUSINESS
SIGNIFICANT ACCOUNTING POLICIES
2. SIGNIFICANT ACCOUNTING POLICIES
TRANSFER OF PLASMA CENTER ASSETS
3. TRANSFER OF PLASMA CENTER ASSETS
INVENTORIES
4. INVENTORIES
PROPERTY AND EQUIPMENT
5. PROPERTY AND EQUIPMENT
INTANGIBLE ASSETS
6. INTANGIBLE ASSETS
ACCRUED EXPENSES AND OTHER LIABILITIES
7. ACCRUED EXPENSES AND OTHER LIABILITIES
NOTES PAYABLE
8. NOTES PAYABLE
STOCKHOLDERS' EQUITY
9. STOCKHOLDERS' EQUITY
RELATED PARTY TRANSACTIONS
10. RELATED PARTY TRANSACTIONS
COMMITMENT AND CONTINGENCIES
11. COMMITMENTS AND CONTINGENCIES
INCOME TAXES
12. INCOME TAXES
LEASE OBLIGATIONS
13. LEASE OBLIGATIONS
SEGMENTS
14. SEGMENTS
OTHER EMPLOYEE BENEFITS
15. OTHER EMPLOYEE BENEFITS
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
16. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
CONCENTRATIONS
17. CONCENTRATIONS
SUBSEQUENT EVENTS
18. SUBSEQUENT EVENTS
Principles of consolidation and basis of presentation
Use of estimates
Cash and cash equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Accounts receivable
Receivable [Policy Text Block]
Inventories
Inventory, Policy [Policy Text Block]
Property and equipment
Goodwill
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Impairment of long-lived assets
Revenue recognition
Cost of product revenue
Research and development expenses
Advertising and marketing expenses
Stock-based compensation
Compensation Related Costs, Policy [Policy Text Block]
Income taxes
Earnings (loss) per share
Fair value of financial instruments
Recent accounting pronouncements
Schedule of dilutive securities
Schedule of inventory
Schedule of property and equipment
Schedule of intangible assets
Intangible asset future aggregate amortization expense
Schedule of Accrued expenses and other current liabilities
Summary of outstanding senior notes payable
Summary of the outstanding related party note payable
Schedule of assumptions
Schedule of stock option activity
Summary of outstanding and exercisable options by price range
Schedule of granted Restricted Stock Units
Stock-based compensation expense
Schedule of reconciliation of income taxes
Schedule of deferred tax asset
Schedule of future minimum lease payments
Summarized segment financial information
Schedule of supplemental cash flow information
Consolidated Entities Axis
Plan Name Axis
Jefferies LLC [Member]
Sale Agreement [Member]
Cash and cash equivalents
Accumulated deficit
Working capital
Sales of common stock
Proceeds from sales of common stock
Derivative Instrument [Axis]
Award Type [Axis]
Class of Warrant or Right [Axis]
Stock Options [Member]
Restricted stock units [Member]
Warrants [Member]
Potentially dilutive securities
Restructuring Type [Axis]
Award Date Axis
Property, Plant and Equipment, Type [Axis]
Range [Axis]
Reserve Account [Member]
January 1, 2019 [Member]
Biotest License Agreement [Member]
Buildings [Member]
Land and Buildings [Member]
Maximum [Member]
Minimum [Member]
Goodwill
Vesting period
Vesting term
Advertising and marketing expenses
[Marketing and Advertising Expense]
Cash
Right of use assets
Lease liability
Amortization period
Useful life
TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)
Credit Facility [Axis]
January 1, 2019 [Member]
[January 1, 2019 [Member]]
Two Facilities [Member]
Combined fair value of obligation
Property and equipment and inventory amount
Combined fair value of obligation, gain amount
Raw materials
Work-in-process
Finished goods
Total inventories
Manufacturing and laboratory equipment [Member]
Office equipment and computer software [Member]
Furniture and fixtures [Member]
Leasehold improvements [Member]
Land [Member]
Buildings and building improvements [Member]
Construction in process [Member]
Property, plant and equipments, gross
Less: accumulated depreciation
[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]
Total Property, plant and equipments, net
Depreciation expense
Finite Lived Intangible Assets By Major Class Axis
Trademark and other intangible rights related to Nabi-HB
Right to intermediates
Customer contract
Cost
Accumulated amortization
Net
2021
2022
2023
2024
INTANGIBLE ASSETS (Details Narrative)
Amortization of intangible assets
Accrued incentives
Accrued rebates
Accrued payroll
Accrued distribution fees
Accrued testing
Other
Total accrued expenses and other current liabilities
Notes payable
Less: debt discount
Senior notes payable
Subordinated note payable to Biotest
Less:
Debt discount
Subordinated note payable
Investment Secondary Categorization [Axis]
Title Of Individual Axis
Short-term Debt, Type [Axis]
First Perceptive Amendment [Member]
BPC (Member)
Perceptive Credit Agreement [Member]
Perceptive Tranche IV Warrant [Member]
Perceptive Tranche III Warrant [Member]
Perceptive Tranche IV Loan (Member)
Perceptive Tranche I Loan (Member)
Perceptive Tranche II Loan (Member)
Perceptive Tranche III Loan (Member)
Marathon Healthcare Finance Fund, L.P. [Member]
Second Perceptive Amendment [Member]
Perceptive Tranche I Note and Perceptive Tranche II fees paid
Effective interest rate
Additional facility fee
Expiration date
Net Cash proceeds
Description of prepaid principal amount
Fair value of warrants
Warrant exercise price per share
Interest rate description
Additional description
Principal amount of term loan
Shares issued upon exercise of warrants, Amount
Expiry date of warrant
Gain (loss) on extinguishment of debt
Discount rate
Deferred facility fee
Prepayment Penalty
Unamortized debt discount
Fees and expenses
Debt service reserve
Accrued interest
Minimum [Member]
Maximum [Member]
Dividend yield
Expected term
Volatility
Risk-free interest rate
Share Repurchase Program [Axis]
Shares [Member]
Weighted Average Exercise Price [Member]
Shares, Outstanding at beginning of period
Shares, Forfeited
Shares, Expired
Shares, Granted
Shares, Exercised
Shares, Outstanding at end of period and expected to vest
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number]
Shares, Options exercisable
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number]
Weighted average exercise price, Beginning of period
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]
Weighted average exercise price, Forfeited
Weighted average exercise price, Expired
Weighted average exercise price, Granted
Weighted average exercise price, Exercised
Weighted average exercise price, Outstanding at end of period and expected to vest
Weighted average exercise price, Options exercisable
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price]
Total [Member]
$2.04 - $3.20
$3.22 - $4.83
$4.84 - $7.26
$7.56 - $10.80
Outstanding at beginning of period
Options outstanding, weighted average remaining contractual life
Options outstanding, weighted average exercise price
Options outstanding, aggregate intrinsic value
Options exercisable
Options exercisable, weighted average remaining contractual life
Options exercisable, weighted average exercise price
Options exercisable, aggregate intrinsic value
Weighted Average Grant Date Fair Value [Member]
Weighted average grant date fair value, beginning
Weighted average grant date fair value, Granted
Weighted average grant date fair value, Vested
Weighted average grant date fair value, Forfeited
Weighted Average Exercise Price at Ending Balance
[Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price]
Outstanding at beginning of period
[Outstanding at beginning of period]
Granted
Vested
Forfeited
Outstanding at end of period
Income Statement Location Axis
Concentration Risk Benchmark [Axis]
Research and Development [Member]
Selling, General and Administrative [Member]
Plasma Center Operating Expenses [Member]
Cost of goods sold [Member]
Total stock-based compensation expense
January 1, 2021 [Member]
Perceptive Tranche III Warrant [Member]
May 3, 2019 [Member]
Sale Agreement [Member]
Equity Incentive Plans [Member]
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, outstanding
Stock options exercised, shares
Common stock, par value
Common stock, shares issued
Common stock, shares authorized
Common stock, shares outstanding
Underwritten public offering
Proceeds from issuance of shares
Net proceeds from the issuance of common stock
Common stock issuable
Warrants outstanding
Weighted average exercise price of warrants
Warrant exercise price per share
Dividend yield
Expected term
Fair value of warrants
Shares issued upon exercise of warrants, Amount
Risk-free interest rate
Volatility
Shares issuance
Common stock issuable under agreement
Common stock shares sold during the period
Unrecognized compensation expense recognition period
Description maximum number of shares reserved for grant
Weighted average remaining contractual life of stock options outstanding
Unrecognized compensation expense
Stock-based compensation expense
[Employee Benefits and Share-based Compensation]
Compensation expense
Common stock granted
Related Party Transactions By Related Party Axis
Collateral [Axis]
Areth, LLC [Member]
Medical equipment and services [Member]
Credit facility
Rent expense
Monthly Rent
Lease service agreement, frequency of periodic payment
Purchase medical equipment accessories
Plasma supply agreement term
Benefit at U.S. Federal statutory rate
State taxes - deferred
Increase in valuation allowance
Research and development credits
Other
[Effective Income Tax Rate Reconciliation, Other Adjustments, Amount]
Benefit for income taxes
Federal and state net operating loss carryforwards
Federal and state research credits
Interest expense limitations carryforwards
Transaction costs
Deferred revenue
Accrued expenses and other
Total gross deferred tax assets
Less: valuation allowance for deferred tax assets
[Deferred Tax Assets, Valuation Allowance]
Net deferred tax assets
Tax Credit Carryforward Axis
Federal
State
Description tax benefits
Net operating loss carryforwards
Research and development tax credit carryforwards
Net operating loss carry forwards write-offs
Year ended December 31, 2021
2022
[Operating Leases, Future Minimum Payments, Due in Two Years]
2023
[Operating Leases, Future Minimum Payments, Due in Three Years]
2024
[Operating Leases, Future Minimum Payments, Due in Four Years]
2025
Thereafter
Total payments
Less: imputed interest
[Less: imputed interest]
Current portion
[Operating Lease, Liability, Current]
Total
[Total]
January 1, 2019 [Member]
Aggregate lease expense
Lease description
Operating Lease liabilities
Weighted average remaining term
Incremental borrowing rate
Cash payments for lease
Right of use asstes
Statement Business Segments Axis
ADMA BioManufacturing
Plasma Collection Centers
Corporate
Consolidated (member)
Revenues
Cost of product revenue
Loss from operations
Interest and other expense, net
Gain on transfer of plasma center assets
[Gain (Loss) on Disposition of Other Assets]
Loss/Gain on the extinguishment of debt
Capital expenditure
Depreciation and amortization expense
TOTAL ASSETS
Compensation expense
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)
SUPPLEMENTAL INFORMATION:
Cash paid for interest
Noncash Financing and Inesting Activities:
Equipment acquired reflected in accounts payable and accrued liabilities
Right-to-use assets obtained in exchange for lease obligations
Warrants issued in connection with note payable
[Warrants issued in connection with note payable]
Major Customers Axis
Financial Instrument Axis
Inventory [Axis]
Two Customers
Accounts Receivable [Member]
Three Customers
Revenues [Member]
Inventory Purchases [Member]
Grifols [Member]
Concentration of credit risk
Inventory purchase
Subsequent Event Type Axis
Jefferies LLC [Member]
Subsequent Event [Member]
Proceeds from issuance of common stock
Remaining gross balance that can be raised
Common stock shares sold during the period
Common stock offering
Amount of gain (loss) on sale or disposal of other assets.
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
Number of options vested.
Weighted average grant-date fair value of non-vested options forfeited.
Number of options outstanding, including both vested and non-vested options.
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Amount of lease obligation due within one year or the normal operating cycle, if longer.
The portion of a bond liability that will not be paid within the upcoming year is classified as a noncurrent liability.
Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Description of the frequency of periodic payments (monthly, quarterly, annual).
Cash received on stock transaction after deduction of issuance costs.
Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.